Efficacy of a Combination of N-Palmitoylethanolamide, Beta-Caryophyllene, Carnosic Acid, and Myrrh Extract on Chronic Neuropathic Pain: A Preclinical Study
Laboratory studyOther animalsWith beta-caryophyllene, carnosic acid and myrrh extract (a commercial combination product, Noxiall)
This study tested palmitoylethanolamide together with beta-caryophyllene, carnosic acid and myrrh extract (a commercial combination product, Noxiall). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice with chronic constriction injury (CCI) of the sciatic nerve, a neuropathic pain model
- Dose used in the study
- Noxiall (PEA, beta-caryophyllene, carnosic acid, myrrh extract), compared with gabapentin or pregabalin, and combined with sub-effective pregabalin doses
- Duration
- Not stated in the abstract
- What was measured
- Mechanical allodynia and thermal hyperalgesia after sciatic nerve injury
What the authors reported
This laboratory study found:
- CCI increased mechanical allodynia and thermal hyperalgesia.
- Noxiall, gabapentin and pregabalin each reduced mechanical allodynia, with Noxiall's effect similar in size to gabapentin or pregabalin.
- Combining sub-effective doses of Noxiall and pregabalin gave a significant reduction in pain, suggesting an additive effect.
- Noxiall also reduced thermal hyperalgesia.
Limits of this study
A mouse model of nerve injury pain; it cannot show effect in people. Funding and conflicts not stated in the abstract.
Source
PubMed 31316381 · doi:10.3389/fphar.2019.00711
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.